HomeCompareLIAN vs YUM

LIAN vs YUM: Dividend Comparison 2026

LIAN yields 134.80% · YUM yields 1.85%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LIAN wins by $14.61M in total portfolio value
10 years
LIAN
LIAN
● Live price
134.80%
Share price
$0.32
Annual div
$0.43
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$14.72M
Annual income
$5,984,170.20
Full LIAN calculator →
YUM
YUM
● Live price
1.85%
Share price
$155.48
Annual div
$2.88
5Y div CAGR
51.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$107.0K
Annual income
$39,957.33
Full YUM calculator →

Portfolio growth — LIAN vs YUM

📍 LIAN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLIANYUM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LIAN + YUM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LIAN pays
YUM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LIAN
Annual income on $10K today (after 15% tax)
$11,457.68/yr
After 10yr DRIP, annual income (after tax)
$5,086,544.67/yr
YUM
Annual income on $10K today (after 15% tax)
$157.45/yr
After 10yr DRIP, annual income (after tax)
$33,963.73/yr
At 15% tax rate, LIAN beats the other by $5,052,580.94/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LIAN + YUM for your $10,000?

LIAN: 50%YUM: 50%
100% YUM50/50100% LIAN
Portfolio after 10yr
$7.41M
Annual income
$3,012,063.76/yr
Blended yield
40.64%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on YUM right now

LIAN
Analyst Ratings
1
Buy
1
Hold
1
Sell
Consensus: Buy
Altman Z
-2.4
Piotroski
2/9
YUM
Analyst Ratings
18
Buy
30
Hold
3
Sell
Consensus: Hold
Price Target
$173.15
+11.4% upside vs current
Range: $158.00 — $190.00
Altman Z
2.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LIAN buys
0
YUM buys
0
No recent congressional trades found for LIAN or YUM in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLIANYUM
Forward yield134.80%1.85%
Annual dividend / share$0.43$2.88
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.4%
Portfolio after 10y$14.72M$107.0K
Annual income after 10y$5,984,170.20$39,957.33
Total dividends collected$13.51M$80.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusBuyHold

Year-by-year: LIAN vs YUM ($10,000, DRIP)

YearLIAN PortfolioLIAN Income/yrYUM PortfolioYUM Income/yrGap
1← crossover$24,180$13,479.62$10,980$280.44+$13.2KLIAN
2$56,333$30,460.96$12,185$435.72+$44.1KLIAN
3$126,601$66,324.55$13,722$684.14+$112.9KLIAN
4$274,767$139,304.02$15,773$1,090.14+$259.0KLIAN
5$576,559$282,557.87$18,650$1,773.02+$557.9KLIAN
6$1,171,036$554,118.18$22,921$2,966.37+$1.15MLIAN
7$2,304,838$1,051,829.48$29,685$5,158.69+$2.28MLIAN
8$4,400,957$1,934,780.61$41,216$9,453.02+$4.36MLIAN
9$8,161,691$3,452,667.04$62,672$18,571.31+$8.10MLIAN
10$14,717,180$5,984,170.20$107,016$39,957.33+$14.61MLIAN

LIAN vs YUM: Complete Analysis 2026

LIANStock

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor for ulcerative colitis and Crohn's disease; NX-13 for ulcerative colitis; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03, an eye solution for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.

Full LIAN Calculator →

YUMConsumer Discretionary

YUM! Brands, Inc., together with its subsidiaries, develops, operates, and franchises quick service restaurants worldwide. It operates through four segments: the KFC Division, the Taco Bell Division, the Pizza Hut Division, and the Habit Burger Grill Division. The company operates restaurants under the KFC, Pizza Hut, Taco Bell, and The Habit Burger Grill brands, which specialize in chicken, pizza, made-to-order chargrilled burgers, sandwiches, Mexican-style food categories, and other food products. As of December 31, 2021, it had 26,934 KFC units; 18,381 Pizza Hut units; 7,791 Taco Bell units; and 318 The Habit Burger Grill units in approximately 157 countries and territories. The company was formerly known as TRICON Global Restaurants, Inc. and changed its name to YUM! Brands, Inc. in May 2002. YUM! Brands, Inc. was incorporated in 1997 and is headquartered in Louisville, Kentucky.

Full YUM Calculator →
📬

Get this LIAN vs YUM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LIAN vs SCHDLIAN vs JEPILIAN vs OLIAN vs KOLIAN vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.